Business Context and Reporting Period
This Form 8-K Current Report was filed by IDEAYA Biosciences, Inc. on April 6, 2022, covering events occurring on April 5, 2022. The filing primarily addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased its size from eight to nine members.
- New Appointment: Catherine J. Mackey, Ph.D., was appointed as a Class I independent director, effective April 5, 2022.
- Term: Dr. Mackey's initial term expires at the Company's 2023 annual meeting of stockholders.
Compensation and Governance Details
- Equity Grant: Dr. Mackey received an option to purchase 22,000 shares of common stock.
- Exercise Price: Set at the closing price of the Company's common stock on April 5, 2022.
- Vesting Schedule: The option vests monthly, with 1/36th of the shares becoming exercisable on each monthly anniversary of the appointment date, contingent on continued service.
- Committee Assignments: Dr. Mackey has not been named to any Board committees at this time.
- Indemnification: A standard director and officer indemnification agreement was executed.
Investor Verification Checklist
- Verify the closing stock price on April 5, 2022, to determine the exercise price of the 22,000 share option granted to Dr. Mackey.
- Review the Company's Definitive Proxy Statement on Schedule 14A (filed April 19, 2021) for details on the non-employee director compensation program.
- Confirm Dr. Mackey's professional background and independence status as disclosed in the press release (Exhibit 99.1).
- Monitor future filings for any committee assignments or changes to Dr. Mackey's director term.